Dr Daniels is a partner with 5AM Venture Management, LLC, and member
of the Board of Cabaletta Bio, Inc., both in the US.
From 2000 to 2014 Dr Daniels held various management positions at
Bristol-Myers Squibb Pharmaceutical group, US. Most recently as Senior
Vice President for Global Development and Medical Affairs and as a
member of the senior management team. From 1996 to 2000 Dr Daniels
held a series of leadership positions at Merck Research Laboratories,
Dr Daniels was first elected to the Board of Novo Nordisk A/S in 2016 and has most recently been re-elected in March 2020. His term as a board member expires in March 2021.
In March 2020, the Board of Directors of Novo Nordisk A/S assessed that Dr Daniels is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen.
Dr Daniels became member of the Research & Development Committee
at Novo Nordisk A/S at the establishment in March 2017 and Dr Daniels
became member of the Remuneration Committee at Novo Nordisk A/S in
In January 2020, the Board of Directors assessed that the special
competences possessed by Dr Daniels that are important for the
performance of his duties are his extensive experience in clinical
development, medical affairs and corporate strategy across a broad
range of therapeutics areas within the pharmaceutical industry,
especially in the US.
1987: MD from Washington University, St. Louis, US
1981: MA in Metabolism and Nutritional Biochemistry, Massachusetts Institute of Technology, Cambridge, US
1981: BSc in Life Sciences, Massachusetts Institute of Technology,
Dr Daniels is a US national, born February 1959.